Keros Therapeutics appoints Simon Cooper as CMO effective Aug 2; Ordonez departs

Keros Therapeutics, Inc.

Simon Cooper appointed CMO effective Aug 2, 2021; succeeds Claudia Ordonez who departed July 30.
Dr. Cooper previously SVP/CMO at Kadmon; prior roles at Anokion, AbbVie, Sanofi, Novartis.
Ordonez gets 9-month base salary severance, acceleration on 7,603 options, COBRA up to 9 months, $5k consulting fee.
Cooper receives $450k base salary, 40% target bonus, option for 60,000 shares.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Simon Cooper

Chief Medical Officer

KROS · Keros Therapeutics, Inc.

Effective: 2021-08-02
Filed: August 2, 2021, 7:59 PM ET

Simon Cooper, M.B.B.S., has been appointed to serve as the Company’s Chief Medical Officer, effective as of August 2, 2021

Departed

Claudia Ordonez

Chief Medical Officer

KROS · Keros Therapeutics, Inc.

Effective: 2021-07-30
Successor: Simon Cooper
Filed: August 2, 2021, 7:59 PM ET

Dr. Cooper is succeeding Claudia Ordonez, M.D., who departed from the Chief Medical Officer position effective July 30, 2021

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Simon Cooper was appointed as Chief Medical Officer at Keros Therapeutics, Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

Simon Cooper, M.B.B.S., has been appointed to serve as the Company’s Chief Medical Officer, effective as of August 2, 2021

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Claudia Ordonez departed as Chief Medical Officer at Keros Therapeutics, Inc..

Action: departed
Role: Chief Medical Officer

Exact text from the filing

Dr. Cooper is succeeding Claudia Ordonez, M.D., who departed from the Chief Medical Officer position effective July 30, 2021

View on SEC.gov

Keros Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001664710-21-000048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.